Skip to main content

Patient Recruitment Home

Current Protocols

Ethics in Clinical Research

Privacy Notice

FAQ About Clinical Studies

Contact Us

Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.

For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).

Se habla español.

Patient Recruitment

Do You or Someone You Know Have Biliary Tract Carcinoma?

Testing Immune-based Strategies in Biliary Tract Cancers

Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are studying the use of an immunotherapy medication called Pembrolizumab, with two other chemotherapy medications, Capecitabine and Oxaliplatin. Oxaliplatin and Capecitabine are widely used to treat different types of gastrointestinal cancers. The researchers want to see if when these medications are used together, they will support the immune system to better fight cancer cells. Pembrolizumab targets PD-1, a protein found on T cells that helps control your body's immune system response. When PD-1 attaches to PD-L1 (a protein found on some cancer cells), it can stop T cells from killing the cancer cells. Therapies like Pembrolizumab can make it harder for cancer cells to hide from T cells, so that the immune system can find them and try to attack them. We hope this combination when given together, may result in a new a way of treating patients with biliary tract carcinoma (BTC).

INCLUSION CRITERIA:

  • 18 years or older
  • Patient must have confirmation of biliary tract carcinoma
  • Patient previously treated for biliary tract carcinoma and it has metastasized
  • Patient must have received, been intolerant of and/or refused at least one line of chemotherapy

EXCLUSION CRITERIA:

  • Patient who has undergone liver transplant
  • Patient with known brain metastases
  • History of chronic autoimmune disease

The NIH Clinical Center, America's Research Hospital located in Bethesda, MD Metro red line (Medical Center stop)

For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
For those who are Deaf, Hard-of-Hearing, or Speech Impaired
800-877-8339 TTY/ASCII
Se habla español
Email: PRPL@cc.nih.gov

Or go online:
https://go.usa.gov/xpKfg
Refer to NIH study 17-C-0082

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 02/25/2020

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at http://www.cc.nih.gov/disclaimers.html